Welcome to our dedicated page for Privia Health Group SEC filings (Ticker: PRVA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Privia Health Group, Inc. files SEC reports that document its physician enablement business, operating results, governance and public-company capital structure. Its 8-K reports commonly furnish quarterly and annual financial releases, including revenue, care margin, platform contribution, adjusted EBITDA, guidance, value-based risk arrangements and provider-network growth.
Proxy and other material-event filings cover board and committee governance, shareholder voting matters, material agreements, risk factors, regulatory disclosures and other updates tied to a Delaware corporation listed on Nasdaq under PRVA.
KING DAVID P reported acquisition or exercise transactions in this Form 4 filing.
Privia Health Group, Inc. director David P. King reported an equity compensation grant rather than an open-market trade. On May 20, 2026, he received 8,463 restricted stock units under the company’s 2021 Omnibus Incentive Plan at no cash cost. These RSUs will vest on the earlier of the day immediately preceding the company’s 2027 annual meeting of stockholders or the first anniversary of the grant date. Following this award, he holds 50,775 common shares directly, showing this filing reflects routine director compensation in stock-based form.
Privia Health Group, Inc. director Francis S. Soistman Jr. filed an initial Form 3, which is a required statement of beneficial ownership for insiders. The filing shows no reported transactions and no share positions or derivative holdings at this time for the reporting person.
Privia Health Group, Inc. reported the results of its 2026 Annual Meeting of Stockholders, where all proposals were approved. Stockholders elected three Class I directors — Nancy Cocozza, David King, and Francis Soistman — to terms running until the 2029 annual meeting.
Stockholders also approved, on an advisory and non-binding basis, the compensation of the company’s named executive officers, with 103,956,500 votes cast in favor. In addition, the appointment of PricewaterhouseCoopers LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026 received strong support, with 117,343,159 votes for and minimal opposition.
Privia Health Group, Inc. Chief Executive Officer Parth Mehrotra reported open-market sales of company common stock. He sold 105,439 shares on May 11 at a weighted average price of $22.55 per share and 15,647 shares on May 12 at a weighted average price of $22.64 per share, for total reported sales of 121,086 shares.
According to the footnotes, these sales were effected under a Rule 10b5-1 trading plan, and certain shares were sold on a nondiscretionary "sell to cover" basis to satisfy tax withholding on vested restricted stock units. After these transactions, Mehrotra directly holds 434,357 shares of Privia Health Group common stock. The filing notes that actual sale prices ranged from $22.28 to $23.10 per share.
Privia Health Group, Inc. executive vice president and chief financial officer David Mountcastle reported a small share sale linked to equity compensation. He sold 3,385 shares of common stock at $22.60 per share in a nondiscretionary “sell to cover” transaction to satisfy tax withholding obligations arising from the vesting and settlement of restricted stock units. After this transaction, he directly holds 211,462 shares of common stock and also has indirect ownership of 8,695 shares through his spouse.
Parth Mehrotra submitted a Form 144 notice regarding proposed sales of Common Stock. The filing lists 15,647 shares tied to restricted stock vesting dated 05/09/2026 and reports multiple reported dispositions in March–May 2026 totaling several transactions.
The record lists broker Fidelity Brokerage Services LLC and shows individual past sales on 03/06/2026, 03/09/2026, 03/10/2026, 03/12/2026, 03/13/2026, 03/16/2026, and 05/11/2026 with per‑trade share counts and proceeds reported in the filing.
Parth Mehrotra reported proposed sales of Common Stock of PRVA via Form 144. The notice lists restricted stock vesting entries of 30,538 shares on 03/11/2026, 30,072 shares on 03/12/2026, and 30,793 shares on 03/13/2026. The filing also records open-market dispositions during March: 21,440 shares on 03/06/2026 for $496,357.44, 41,999 shares on 03/09/2026 for $960,197.55, 21,097 shares on 03/10/2026 for $479,144.34, 26,763 shares on 03/12/2026 for $586,096.32, 27,229 shares on 03/13/2026 for $586,096.06, and 26,509 shares on 03/16/2026 for $586,108.69.
Affiliate filed a Form 144 reporting a proposed sale of 3,385 shares. The filing lists the securities to be sold as 3,385 shares tied to restricted stock vesting dated 05/08/2026. The excerpt also itemizes multiple past sales by David Mountcastle on various dates in 2026.
PRVA reported a Form 144 notice for the proposed sale of 14,036 shares of Common Stock. The filing lists the sale method as Restricted Stock Vesting and identifies the issuer as the seller on 05/08/2026. The filing also discloses multiple completed Common stock sales by Parth Mehrotra in March 2026, with individual transactions and gross proceeds reported for each date.
Privia Health Group, Inc. reported strong growth for the three months ended March 31, 2026, with revenue rising to $603.8 million from $480.1 million, driven mainly by higher fee-for-service patient care and value-based care revenue.
Care Margin increased to $128.7 million, Platform Contribution to $67.0 million, and Adjusted EBITDA to $36.7 million, showing improved operating leverage. Net income attributable to Privia Health declined to $3.1 million from $4.2 million as a higher effective tax rate and increased stock-based compensation offset operating gains.